Roberta Ciarapica

Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21 Cip1 expression and hampers tumour cell growth in vitro and in vivo

Rhabdomyosarcoma (RMS) is a paediatric soft-tissue sarcoma arising from skeletal muscle precursors coexpressing markers of proliferation and differentiation. Inducers of myogenic differentiation suppress RMS tumourigenic phenotype. The Notch target gene HES1 is upregulated in RMS and prevents tumour cell differentiation in a Notch-dependent manner. However, Notch receptors regulating this phenomenon are unknown. In agreement with data in RMS primary tumours, we show here that the Notch3 receptor is overexpressed in RMS cell lines versus normal myoblasts. Notch3-targeted downregulation in RMS cells induces hyper-phosphorylation of p38 and Akt essential for myogenesis, resulting in the differentiation of tumour cells into multinucleated myotubes expressing Myosin Heavy Chain. These phenomena are associated to a marked decrease in HES1 expression, an increase in p21Cip1 level and the accumulation of RMS cells in the G1 phase. HES1-forced overexpression in RMS cells reverses, at least in part, the pro-differentiative effects of Notch3 downregulation. Notch3 depletion also reduces the tumourigenic potential of RMS cells both in vitro and in vivo. These results indicate that downregulation of Notch3 is sufficient to force RMS cells into completing a correct full myogenic program providing evidence that it contributes, partially through HES1 sustained expression, to their malignant phenotype. Moreover, they suggest Notch3 as a novel potential target in human RMS.

The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx)

The Polycomb group (PcG) proteins regulate stem cell differentiation via the repression of gene transcription, and their deregulation has been widely implicated in cancer development. The PcG protein Enhancer of Zeste Homolog 2 (EZH2) works as a catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) by methylating lysine 27 on histone H3 (H3K27me3), a hallmark of PRC2-mediated gene repression. In skeletal muscle progenitors, EZH2 prevents an unscheduled differentiation by repressing muscle-specific gene expression and is downregulated during the course of differentiation. In rhabdomyosarcoma (RMS), a pediatric soft-tissue sarcoma thought to arise from myogenic precursors, EZH2 is abnormally expressed and its downregulation in vitro leads to muscle-like differentiation of RMS cells of the embryonal variant. However, the role of EZH2 in the clinically aggressive subgroup of alveolar RMS, characterized by the expression of PAX3-FOXO1 oncoprotein, remains unknown. We show here that EZH2 depletion in these cells leads to programmed cell death. Transcriptional derepression of F-box protein 32 (FBXO32) (Atrogin1/MAFbx), a gene associated with muscle homeostasis, was evidenced in PAX3-FOXO1 RMS cells silenced for EZH2. This phenomenon was associated with reduced EZH2 occupancy and H3K27me3 levels at the FBXO32 promoter. Simultaneous knockdown of FBXO32 and EZH2 in PAX3-FOXO1 RMS cells impaired the pro-apoptotic response, whereas the overexpression of FBXO32 facilitated programmed cell death in EZH2-depleted cells. Pharmacological inhibition of EZH2 by either 3-Deazaneplanocin A or a catalytic EZH2 inhibitor mirrored the phenotypic and molecular effects of EZH2 knockdown in vitro and prevented tumor growth in vivo. Collectively, these results indicate that EZH2 is a key factor in the proliferation and survival of PAX3-FOXO1 alveolar RMS cells working, at least in part, by repressing FBXO32. They also suggest that the reducing activity of EZH2 could represent a novel adjuvant strategy to eradicate high-risk PAX3-FOXO1 alveolar RMS.

Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.

BackgroundEmbryonal Rhabdomyosarcoma (RMS) is a pediatric soft-tissue sarcoma derived from myogenic precursors that is characterized by a good prognosis in patients with localized disease. Conversely, metastatic tumors often relapse, leading to a dismal outcome. The histone methyltransferase EZH2 epigenetically suppresses skeletal muscle differentiation by repressing the transcription of myogenic genes. Moreover, de-regulated EZH2 expression has been extensively implied in human cancers. We have previously shown that EZH2 is aberrantly over-expressed in RMS primary tumors and cell lines. Moreover, it has been recently reported that EZH2 silencing in RD cells, a recurrence-derived embryonal RMS cell line, favors myofiber-like structures formation in a pro-differentiation context. Here we evaluate whether similar effects can be obtained also in the presence of growth factor-supplemented medium (GM), that mimics a pro-proliferative microenvironment, and by pharmacological targeting of EZH2 in RD cells and in RD tumor xenografts.MethodsEmbryonal RMS RD cells were cultured in GM and silenced for EZH2 or treated with either the S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin A (DZNep) that induces EZH2 degradation, or with a new class of catalytic EZH2 inhibitors, MC1948 and MC1945, which block the catalytic activity of EZH2. RD cell proliferation and myogenic differentiation were evaluated both in vitro and in vivo.ResultsHere we show that EZH2 protein was abnormally expressed in 19 out of 19 (100%) embryonal RMS primary tumors and cell lines compared to their normal counterparts. Genetic down-regulation of EZH2 by silencing in GM condition reduced RD cell proliferation up-regulating p21Cip1. It also resulted in myogenic-like differentiation testified by the up-regulation of myogenic markers Myogenin, MCK and MHC. These effects were reverted by enforced over-expression of a murine Ezh2, highlighting an EZH2-specific effect. Pharmacological inhibition of EZH2 using either DZNep or MC inhibitors phenocopied the genetic knockdown of EZH2 preventing cell proliferation and restoring myogenic differentiation both in vitro and in vivo.ConclusionsThese results provide evidence that EZH2 function can be counteracted by pharmacological inhibition in embryonal RMS blocking proliferation even in a pro-proliferative context. They also suggest that this approach could be exploited as a differentiation therapy in adjuvant therapeutic intervention for embryonal RMS.

Oxidative Stress-Induced miR-200c Disrupts the Regulatory Loop Among SIRT1, FOXO1, and eNOS

AIMS Reactive oxygen species (ROS) play a pivotal role in different pathologic conditions, including ischemia, diabetes, and aging. We previously showed that ROS enhance miR-200c expression, causing endothelial cell (EC) apoptosis and senescence. Herein, we dissect the interaction among miR-200c and three strictly related proteins that modulate EC function and ROS production: sirtuin 1 (SIRT1), endothelial nitric oxide synthase (eNOS), and forkhead box O1 (FOXO1). Moreover, the role of miR-200c on ROS modulation was also investigated. RESULTS We demonstrated that miR-200c directly targets SIRT1, eNOS, and FOXO1; via this mechanism, miR-200c decreased NO and increased the acetylation of SIRT1 targets, that is, FOXO1 and p53. FOXO1 acetylation inhibited its transcriptional activity on target genes, that is, SIRT1 and the ROS scavengers, catalase and manganese superoxide dismutase. In keeping, miR-200c increased ROS production and induced p66Shc protein phosphorylation in Ser-36; this mechanism upregulated ROS and inhibited FOXO1 transcription, reinforcing this molecular circuitry. These in vitro results were validated in three in vivo models of oxidative stress, that is, human skin fibroblasts from old donors, femoral arteries from old mice, and a murine model of hindlimb ischemia. In all cases, miR-200c was higher versus control and its targets, that is, SIRT1, eNOS, and FOXO1, were downmodulated. In the mouse hindlimb ischemia model, anti-miR-200c treatment rescued these targets and improved limb perfusion. Innovation and Conclusion: miR-200c disrupts SIRT1/FOXO1/eNOS regulatory loop. This event promotes ROS production and decreases NO, contributing to endothelial dysfunction under conditions of increased oxidative stress such as aging and ischemia. Antioxid. Redox Signal. 27, 328-344.

Oxidative stress, microRNAs and cytosolic calcium homeostasis.

Reactive oxygen species increase cytosolic [Ca(2+)], (Cai), and also modulate the expression of some microRNAs (miRNAs), however the link among oxidative stress, miRNAs and Cai is poorly characterized. In this review we have focused on three groups of miRNAs: (a) miRNAs that are modulated both by ROS and Cai: miR-181a and miR-205; (b) miRNAs that are modulated by ROS and have an effect on Cai: miR-1, miR-21, miR-24, miR-25, miR-185 and miR-214; (c) miRNAs that modulate both ROS and Cai: miR-133; miR-145, miR-495, and we have analyzed their effects on cell signaling and cell function. Finally, in the last section we have examined the role of these miRNAs in the skin, under conditions associated with enhanced oxidative stress, i.e. skin aging, the response to ultraviolet light and two important skin diseases, psoriasis and atopic dermatitis. It is apparent that although some experimental evidence is already available on (a) the role of Cai in miRNAs expression and (b) on the ability of some miRNAs to modulate Cai-dependent intracellular signaling, these research lines are still largely unexplored and represent important areas of future studies.

Prolyl isomerase Pin1 and protein kinase HIPK2 cooperate to promote cortical neurogenesis by suppressing Groucho/TLE:Hes1-mediated inhibition of neuronal differentiation.

The Groucho/transducin-like Enhancer of split 1 (Gro/TLE1):Hes1 transcriptional repression complex acts in cerebral cortical neural progenitor cells to inhibit neuronal differentiation. The molecular mechanisms that regulate the anti-neurogenic function of the Gro/TLE1:Hes1 complex during cortical neurogenesis remain to be defined. Here we show that prolyl isomerase Pin1 (peptidyl-prolyl cis-trans isomerase NIMA-interacting 1) and homeodomain-interacting protein kinase 2 (HIPK2) are expressed in cortical neural progenitor cells and form a complex that interacts with the Gro/TLE1:Hes1 complex. This association depends on the enzymatic activities of both HIPK2 and Pin1, as well as on the association of Gro/TLE1 with Hes1, but is independent of the previously described Hes1-activated phosphorylation of Gro/TLE1. Interaction with the Pin1:HIPK2 complex results in Gro/TLE1 hyperphosphorylation and weakens both the transcriptional repression activity and the anti-neurogenic function of the Gro/TLE1:Hes1 complex. These results provide evidence that HIPK2 and Pin1 work together to promote cortical neurogenesis, at least in part, by suppressing Gro/TLE1:Hes1-mediated inhibition of neuronal differentiation.

MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma

BackgroundRhabdomyosarcoma (RMS) is a pediatric soft tissue sarcoma arising from myogenic precursors that have lost their capability to differentiate into skeletal muscle. The polycomb-group protein EZH2 is a Lys27 histone H3 methyltransferase that regulates the balance between cell proliferation and differentiation by epigenetically silencing muscle-specific genes. EZH2 is often over-expressed in several human cancers acting as an oncogene. We previously reported that EZH2 inhibition induces cell cycle arrest followed by myogenic differentiation of RMS cells of the embryonal subtype (eRMS). MiR-101 is a microRNA involved in a negative feedback circuit with EZH2 in different normal and tumor tissues. To that, miR-101 can behave as a tumor suppressor in several cancers by repressing EZH2 expression. We, therefore, evaluated whether miR-101 is de-regulated in eRMS and investigated its interplaying with EZH2 as well as its role in the in vitro tumorigenic potential of these tumor cells.ResultsHerein, we report that miR-101 is down-regulated in eRMS patients and in tumor cell lines compared to their controls showing an inverse pattern of expression with EZH2. We also show that miR-101 is up-regulated in eRMS cells following both genetic and pharmacological inhibition of EZH2. In turn, miR-101 forced expression reduces EZH2 levels as well as restrains the migratory potential of eRMS cells and impairs their clonogenic and anchorage-independent growth capabilities. Finally, EZH2 recruitment to regulatory region of miR-101-2 gene decreases in EZH2-silenced eRMS cells. This phenomenon is associated to reduced H3K27me3 levels at the same regulatory locus, indicating that EZH2 directly targets miR-101 for repression in eRMS cells.ConclusionsAltogether, our data show that, in human eRMS, miR-101 is involved in a negative feedback loop with EZH2, whose targeting has been previously shown to halt eRMS tumorigenicity. They also demonstrate that the re-induction of miR-101 hampers the tumor features of eRMS cells. In this scenario, epigenetic dysregulations confirm their crucial role in the pathogenesis of this soft tissue sarcoma.

The Emerging Role of miR-200 Family in Cardiovascular Diseases

Recent studies have shown that reactive oxygen species increase the expression of miR-200 family (miR-200); however, little is known about this micro-RNA family in the cardiovascular system. In this Viewpoint, we provide evidence suggesting that miR-200 may be important in conditions that affect the heart and blood vessels. Oxidative stress plays a major role in cardiovascular physiopathology and some common conditions including aging, diabetes mellitus, atherosclerosis, and reperfusion injury induce reactive oxygen species (ROS). In 2011, it was first published that endothelial and skeletal muscle cells exposed to oxidative stress, in vitro and in vivo, exhibit a marked increase in miR-2001. Subsequently, ROS ability to induce miR-200 has been confirmed in many cell types. Furthermore, hypoxia enhances miR-429, an miR-200 member, and miR-429 targets HIF-1α (hypoxia-inducible factor-1α) and decreases its expression. Most miR-200 studies have been in the cancer field: miR-200 modulates epithelial–mesenchymal transition by targeting the transcription factors ZEB1 and ZEB2 (Zinc-finger E-box binding homeobox 1 and 2) and circulating miR-200 may represent clinically useful cancer biomarkers. In contrast, the role of miR-200 in CV diseases is still poorly investigated. MiRNAs are short (21–22 nucleotides) noncoding RNAs: their seed sequence (nucleotides 2–8 from the 5′ end) targets specific mRNAs and via this mechanism they inhibit translation and also may modulate mRNA stability. The miR-200 family is composed of 5 members clustered and expressed as 2 separate polycistronic pri-miRNA transcripts: in humans, miR-200c and miR-141 are on chromosome 12; miR-200a, miR-200b, and miR-429 are on chromosome 1. They are also identified by different seed sequences: subgroup I comprises miR-141 and miR-200a; subgroup II includes miR-200b, miR-200c, and miR-429. Because each miRNA can target numerous mRNAs and the 2 miR-200 subgroups have different seed sequences, the functional impact of miR-200 can be profound. The Figure shows the major miR-200c–activated …

Abstract A29: Notch-dependent modulation of microRNAs in rhabdomyosarcoma

Abstract Rhabdomyosarcoma (RMS) is a pediatric tumor that originates from skeletal muscle precursors. Therapeutic strategies aimed at restoring the differentiation potential of RMS tumor cells are accepted as anti-cancer approaches. Therefore, pathways involved in skeletal muscle determination are good potential targets. We have recently demonstrated that Notch3 signaling is over-activated in RMS cell lines of both embryonal and alveolar subtype. Down-regulation of Notch3 expression resulted in cell cycle inhibition of RMS alveolar and embryonal cell lines that showed the appearance of multinucleated structures indicative of skeletal muscle-like myotubes in vitro. Moreover, Notch3 knockdown impaired tumor growth in vivo. Here we expand this study evaluating, through microarrays profiling, the expression of microRNAs 48 hours after Notch3 siRNA treatment compared to that of control siRNA. Several up- or down-regulated microRNAs were detected in both RH30 alveolar and RD embryonal cells. The up-regulation of muscle-specific microRNAs such as miR-1, miR-133 and miR-206 was confirmed 24 and 48 hours post-Notch3 depletion by RT-qPCR. Moreover, non-muscle-specific microRNAs such as miR-26a and miR-214 that cooperate to myogenesis were up-regulated as well. Altogether, these preliminary results indicate that Notch3 prevents the differentiation of RMS cells also through down-regulation of pro-myogenic microRNAs. More deep studies are in course to dissect the Notch3-dependent modulation of these small non-coding RNAs in this soft tissue sarcoma. Citation Format: Rossella Rota, Sr., Roberta Ciarapica, Jr., Letizia Da Sacco, Jr., Maria De Salvo, Jr., Andrea Masotti, Sr., Lucio Miele, Sr., Franco Locatelli, Sr. Notch-dependent modulation of microRNAs in rhabdomyosarcoma [abstract]. In: Proceedings of the AACR Special Conference on Noncoding RNAs and Cancer; 2012 Jan 8-11; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(2 Suppl):Abstract nr A29.